Grace Therapeutics Statistics
Total Valuation
GRCE has a market cap or net worth of $54.31 million. The enterprise value is $37.34 million.
Important Dates
The last earnings date was Thursday, February 12, 2026, before market open.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GRCE has 15.47 million shares outstanding. The number of shares has increased by 36.09% in one year.
| Current Share Class | 15.47M |
| Shares Outstanding | 15.47M |
| Shares Change (YoY) | +36.09% |
| Shares Change (QoQ) | +6.34% |
| Owned by Insiders (%) | 16.53% |
| Owned by Institutions (%) | 14.49% |
| Float | 9.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.86 |
| P/TBV Ratio | 3.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.96
| Current Ratio | 14.96 |
| Quick Ratio | 14.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -10.22% and return on invested capital (ROIC) is -12.01%.
| Return on Equity (ROE) | -10.22% |
| Return on Assets (ROA) | -10.84% |
| Return on Invested Capital (ROIC) | -12.01% |
| Return on Capital Employed (ROCE) | -16.74% |
| Weighted Average Cost of Capital (WACC) | 8.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$996,500 |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +93.58% in the last 52 weeks. The beta is 0.69, so GRCE's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | +93.58% |
| 50-Day Moving Average | 4.03 |
| 200-Day Moving Average | 3.41 |
| Relative Strength Index (RSI) | 40.36 |
| Average Volume (20 Days) | 942,168 |
Short Selling Information
The latest short interest is 1.57 million, so 10.12% of the outstanding shares have been sold short.
| Short Interest | 1.57M |
| Short Previous Month | 390,568 |
| Short % of Shares Out | 10.12% |
| Short % of Float | 16.01% |
| Short Ratio (days to cover) | 4.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.25M |
| Pretax Income | -7.00M |
| Net Income | -5.98M |
| EBITDA | -11.24M |
| EBIT | -11.25M |
| Earnings Per Share (EPS) | -$0.38 |
Full Income StatementBalance Sheet
The company has $18.67 million in cash and n/a in debt, with a net cash position of $18.67 million or $1.21 per share.
| Cash & Cash Equivalents | 18.67M |
| Total Debt | n/a |
| Net Cash | 18.67M |
| Net Cash Per Share | $1.21 |
| Equity (Book Value) | 64.89M |
| Book Value Per Share | 4.19 |
| Working Capital | 17.93M |
Full Balance SheetCash Flow
| Operating Cash Flow | -10.13M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 7,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.13M |
| FCF Per Share | -$0.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
